Gemcitabine for the treatment of metastatic breast cancer
Jones J, Takeda A, Tan SC, Cooper K, Loveman E, Clegg A
Record ID 32013000704
English
Authors' recommendations:
Gemcitabine in combination with paclitaxel, within its licensed indication, is recommended as an option for the treatment of metastatic breast cancer only when docetaxel monotherapy or docetaxel plus capecitabine is also considered appropriate.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.journalslibrary.nihr.ac.uk/hta/hta13Suppl2-01/#/abstract
URL for additional information:
http://www.journalslibrary.nihr.ac.uk/hta/volume-13/suppl-2-article-1
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Cost-Benefit Analysis
- Quality-Adjusted Life Years
- Survival Analysis
- Antineoplastic Agents
- Breast Neoplasms
- Deoxycytidine
- Gemcitabine
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.